Medtronic PLC MDT

What the company does

Medtronic PLC is a large-cap company in the Healthcare sector (Medical Devices), with a market value of $122.0B, based in the USA.

It employs about 95,000 people and has been listed since Jan 13, 1978.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

Cheap or expensive? relatively cheap

Its price-to-earnings (P/E) is 23.4 versus 36.9 for the median of the Healthcare sector in our universe (25 companies) — relatively cheap.

Revenue is growing 14% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 14.3 — they expect higher earnings.

The average analyst price target is 104.62, 10% above the current price (their view, not ours).

The stock sits at 76% of its one-year range (0% = the low, 100% = the high).

The risks

• No risk flags were detected from the data we have.

Strengths

• ✅ Profitable — 15 of every 100 dollars of revenue stays as profit.
• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Most analysts rate it buy (20 vs 0).
• ✅ Pays a dividend (3.0% a year).

What changed this week

Over the past week the stock rose 0.7% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

This week's news

• Medtronic (MDT) Reports Strong Real World Ablation Data At APHRS 2026 finance.yahoo.com · 2026-10-24
  What the article says

  Medtronic (NYSE:MDT) reported positive real world registry results for its Sphere-9 catheter and PulseSelect PFA System at APHRS 2026. The Sphere-9 catheter data covered both atrial and ventricular arrhythmias, with registry outcomes indicating high procedural success rates. PulseSelect PFA System findings highlighted… source ↗

• Medtronic (MDT) Stock Could Be A Bargain On Cash Flow finance.yahoo.com · 2026-10-24
  What the article says

  Medtronic has delivered a solid 51.6% share price gain over the past three years, while rolling out new cardiac devices and digital tools that could reshape how it earns and collects cash. With the stock around US$95.41, the open question is whether that price tag lines up with what the company's cash flows can… source ↗

• Pacemakers Market Forecasts Growth from $5.4 Billion (2025) to $7.5 Billion by 2030, Profiling Medtronic, Abbott, Boston Scientific, Biotronik & 6 Other Key Players finance.yahoo.com · 2026-10-23
  What the article says

  Company Logo 108-Page Report Examines the Shift to Leadless and MRI-Compatible Devices as Rising Arrhythmia Prevalence Drives Demand, While High Procedure Costs, Strict Approvals and Cybersecurity Risks Weigh on Growth Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Pacemakers: Global Markets" has been added to… source ↗

• Global Access Device Market Size, Share, Trends, and Forecast, 2026-2032: Trocar and Single-Port Access Devices | Market to Exceed $1.2 Billion as Advanced Trocars Drive Growth finance.yahoo.com · 2026-10-23
  What the article says

  Company Logo New Report available from Research and Markets, values access devices at just over $990m in 2025, led by Applied Medical, Ethicon and Medtronic — though reprocessing contracts and cheap Asia-Pacific disposables keep prices under pressure Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Access Device Market… source ↗

• GE HealthCare Technologies (GEHC) vs. DHR and MDT: Can a $23.9B Backlog and AI Innovation Drive a Healthcare Re-Rating? finance.yahoo.com · 2026-10-22
  What the article says

  Is GEHC a good stock to buy? We came across a bullish thesis on GE HealthCare Technologies Inc. on Astute Optics - US's Substack. The thesis was published on September 13th, when the stock was trading at $64.25, and GEHC gained 9.30% since then. The gain appears to reflect improving sentiment toward healthcare stocks… source ↗

• Global Intrathecal Pump Market Size, Share, Trends, and Forecast, 2026-2032 | Aging Demand and Longer-Life Devices Support a $360 Million Market by 2032 finance.yahoo.com · 2026-10-22
  What the article says

  Company Logo New Report available from Research and Markets, finds Medtronic ahead of Flowonix and Tricumed in a $350m market expected to reach only about $360m by 2032, as high refill costs, ASP erosion and past recalls weigh Dublin, Oct. 22, 2026 (GLOBE NEWSWIRE) -- "Intrathecal Pump Market Size, Share & Trends… source ↗

What changed since last week

No material change: same valuation verdict, same risk flags, price moved less than 3%.